StockNews.AI
CLLS
StockNews.AI
165 days

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

1. Cellectis will report Q4 2024 results on March 13, 2025. 2. An investor call will follow on March 14, 2025, at 8:00 AM ET. 3. Cellectis develops gene-editing therapies for cancer treatment. 4. They control the full cell and gene therapy value chain. 5. The company's pioneering CAR T-cells are pioneering off-the-shelf solutions.

Earnings
-2.79%Current Return
VS
-2.65%S&P 500
$1.25503/07 04:34 PM EDTEvent Start
$1.2203/10 05:44 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings report could reflect positive financial developments, similar to past quarters. Companies in biotech often see stock price increases following strong earnings and future prospects disclosures.

How important is it?

Earnings reports drive investor sentiment and trading decisions. This report may affect CLLS's price given financial status and business updates shared.

Why Short Term?

Market reaction is expected shortly after Q4 results and earnings call. Investor sentiment could shift quickly based on the announced results and future outlook.

Related Companies

ALCLSCRSPEDITNTLAAVDL
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-225-9448 International: +1-203-518-9708 Conference ID: CLLS24 Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1706599&tp_key=4524940f8f About Cellectis      Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X. TALEN® is a registered trademark owned by Cellectis.  For further information on Cellectis, please contact:      Media contacts:        Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact:        Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com        20250307_FY 2024 earnings call announcement_ENGLISH

Related News